HONGKONG, CHINA--(Marketwired - November 23, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM)
Nasdaq: HCM
Director's Share Dealing
London: Wednesday, November 23, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an average price of GBP18.83 per share on November 18, 2016 and November 21, 2016 under a personal share trading plan (the "Plan"). Pursuant to the Plan, a total of 20,000 Ordinary Shares have now been sold. Previously under the Plan 10,000 Ordinary Shares were sold between October 24, 2016 and October 28, 2016 and announced on November 1, 2016. The Plan was put in place by Mr Howell to facilitate a financial settlement arising from a marital separation agreement.
Following the above sale of 10,000 Ordinary Shares, the holding of Mr Howell is 118,600 Ordinary Shares, representing approximately 0.20% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
----------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------
a)Name Mr Michael Howell
----------------------------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a)Position/status Independent Non-executive Director of Chi-Med
----------------------------------------------------------------------------
b)Initial Initial notification
notification/Amen
dment
----------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a)Name Hutchison China MediTech Limited
----------------------------------------------------------------------------
b)LEI N/A
----------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------------------
a)Description of Ordinary Shares of US$1.00 each DI ISIN: KYG4672N1016
the financial ADS ISIN: US44842L1035
instrument, type
of instrument
Identification
code
----------------------------------------------------------------------------
----------------------------------------------------------------------------
b)Nature of the transaction Sale of 5,000 Ordinary Shares on November 18,
2016 and 5,000 Ordinary Shares on November 21,
2016 at an average price of GBP18.83
----------------------------------------------------------------------------
c)Price(s) and volume(s)
------------------------------------------------
Price(s) Volume(s)
------------------------------------------------
GBP18.80 5,000
------------------------------------------------
GBP18.90 3,000
------------------------------------------------
GBP18.80 2,000
------------------------------------------------
----------------------------------------------------------------------------
d) Aggregated volume: 10,000
Aggregated information Price information: GBP18.83
-Aggregated volume
-Price
----------------------------------------------------------------------------
e)Date of the transaction 2016-11-18 - disposal of 5,000 Ordinary Shares
2016-11-21 - disposal of 5,000 Ordinary Shares
----------------------------------------------------------------------------
f)Place of the transaction London Stock Exchange (XLON)
----------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor
Enquiries
Christian
Hogg, CEO +852 2121 8200
International
Media
Enquiries
Anthony
Carlisle,
Citigate Dewe +44 7973 611 888
Rogerson (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based
Media
Enquiries
Brad Miles,
BMC +1 (917) 570 7340
Communications (Mobile) bmiles@bmccommunications.com
Susan Duffy,
BMC +1 (917) 499 8887
Communications (Mobile) sduffy@bmccommunications.com
Investor
Relations
Matt Beck, The +1 (917) 415 1750
Trout Group (Mobile) mbeck@troutgroup.com
David Dible,
Citigate Dewe +44 7967 566 919
Rogerson (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon
(UK) Limited
Richard Gray /
Andrew Potts +44 (20) 7886 2500
